ISDA

Entry Detail

PDB ID:

8GS6

EMDB ID:

EMD-34221

Keywords:

VIRAL PROTEIN

Title:

Structure of the SARS-CoV-2 BA.2.75 spike glycoprotein (closed state 1)

Biological Source:

Source Organism:

Severe acute respiratory syndrome coronavirus 2

Host Organism:

Homo sapiens

PDB Version:

Deposition Date:

2022-09-05

Release Date:

2022-10-26

Method Details:

Experimental Method:

ELECTRON MICROSCOPY

Resolution:

2.86 Å

Aggregation State:

PARTICLE

Reconstruction Method:

SINGLE PARTICLE

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Spike glycoprotein
Mutations:R682G, R683S, R685G, F817P, A892P, A899P, A942P, K986P, V987P
Chain IDs:A, B, C
Chain Length:1246
Number of Molecules:3
Biological Source:Severe acute respiratory syndrome coronavirus 2

UniProt ID:P0DTC2 Pfam ID:PF16451, PF09408, PF19209, PF01601

Ligand Molecules

NAG

Primary Citation

Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant.

Saito, A, Tamura, T, Zahradnik, J, Deguchi, S, Tabata, K, Anraku, Y, Kimura, I, Ito, J, Yamasoba, D, Nasser, H, Toyoda, M, Nagata, K, Uriu, K, Kosugi, Y, Fujita, S, Shofa, M, Monira Begum, M, Shimizu, R, Oda, Y, Suzuki, R, Ito, H, Nao, N, Wang, L, Tsuda, M, Yoshimatsu, K, Kuramochi, J, Kita, S, Sasaki-Tabata, K, Fukuhara, H, Maenaka, K, Yamamoto, Y, Nagamoto, T, Asakura, H, Nagashima, M, Sadamasu, K, Yoshimura, K, Ueno, T, Schreiber, G, Takaori-Kondo, A, Shirakawa, K, Sawa, H, Irie, T, Hashiguchi, T, Takayama, K, Matsuno, K, Tanaka, S, Ikeda, T, Fukuhara, T, Sato, K.Show

Cell Host Microbe 30 1540 1555.e15 (2022)

PMID: 36272413 DOI: 10.1016/j.chom.2022.10.003

Abstact

The SARS-CoV-2 Omicron BA.2.75 variant emerged in May 2022. BA.2.75 is a BA.2 descendant but is phylogenetically distinct from BA.5, the currently predominant BA.2 descendant. Here, we show that BA.2.75 has a greater effective reproduction number and different immunogenicity profile than BA.5. We determined the sensitivity of BA.2.75 to vaccinee and convalescent sera as well as a panel of clinically available antiviral drugs and antibodies. Antiviral drugs largely retained potency, but antibody sensitivity varied depending on several key BA.2.75-specific substitutions. The BA.2.75 spike exhibited a profoundly higher affinity for its human receptor, ACE2. Additionally, the fusogenicity, growth efficiency in human alveolar epithelial cells, and intrinsic pathogenicity in hamsters of BA.2.75 were greater than those of BA.2. Our multilevel investigations suggest that BA.2.75 acquired virological properties independent of BA.5, and the potential risk of BA.2.75 to global health is greater than that of BA.5.

Legend

Protein

Chemical

Disease

Primary Citation of related structures